NEW YORK, July 7 (GenomeWeb News) - Entelos said yesterday that it has expanded a hematology research collaboration with Johnson & Johnson Pharmaceutical Research & Development that began a year and a half ago.
In the expanded program, Entelos will use its PhysioLab biosimulation technology to study the effect of anti-anemia therapy on patients with different types of anemia. Entelos said it will also use its platform to "explore the impact of patient variability, and provide guidance on optimization of anemia clinical trials."
Entelos and J&JPRD began co-developing developing the Hematopoiesis PhysioLab in January 2004.
Financial terms for the expanded agreement were not provided.